

Cancer Proteometabolomics

Guest Editors:

Prof. Dr. Samir M. Hanash

Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Dr. Johannes Fahrmann

Department of Clinical Cancer Prevention, MD Anderson Cancer Center, The University of Texas, 1515 Holcombe Blvd., Houston, TX 77030, USA


Deadline for manuscript submissions:

closed (20 May 2023)

Message from the Guest Editors

The application of “omic” technologies coupled with advanced statistical approaches (e.g., artificial intelligence) is increasingly being utilized to reveal the molecular drivers of tumorigenesis and to derive novel treatment strategies and biomarkers that inform clinical decision making. While “omic” approaches have largely been advanced in the areas of genomics and transcriptomics, there is considerable interest and merit in exploring proteomics and metabolomics data, as these offer detailed characterization of the functional molecular machinery and the derived biochemical outputs that ultimately effect oncogenesis and shape the tumor microenvironment and tumor–host interaction. Using proteomics, metabolomics, or integrated proteomic and metabolomic approaches in the context of cancer thus has high relevance to the identification of next-generation treatment modalities that target cancer cell dependencies, as well as to biomarkers that inform upon disease status or molecular subtypes. We are soliciting original research articles as well as reviews to contribute to this Special Issue.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)